โ
๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ
โข Adj. EPS: $6.68 (Est. $6.40) โ , +15% YoY.
โข Revenue: $12.14B (Est. $11.95B) โ , +9% YoY.
โข Organic Revenue Growth: +6% YoY.
โข GAAP EPS: $4.64, +9% YoY.
โข GAAP Operating Income: $2.26B, +17% YoY.
โข GAAP Operating Margin: 18.6% (vs. 17.4% YoY).
โข Adj. Operating Income: $2.97B, +15% YoY.
โข Adj. Operating Margin: 24.5% (vs. 23.3% YoY).
โ
๐ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ
โข Q3 Adj. EPS beat consensus by ~4.4%, while revenue exceeded estimates by ~1.6%.
โข Organic revenue grew 6% YoY, supporting 9% reported growth and double-digit adjusted earnings expansion.
โข Adjusted operating margin expanded 120 bps YoY to 24.5%, while GAAP operating margin improved 120 bps to 18.6%.
โข Thermo Fisher launched new analytical and diagnostic technologies, including the Orbitrap Isora mass spectrometer, EMPAD G2 electron detector and Ion 560 sequencing chip.
โข Partnered with Mayo Clinic to launch Precure, combining data from over 1M patient samples with proteomics technologies to advance early disease detection.
โข Opened its first AI-Automation Innovation Center in South Korea and completed the divestiture of its microbiology business.
โข Updated FY2026 financial guidance will be provided during the earnings conference call.
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐จ๐ฆ๐ฆ๐๐ง๐ญ๐๐ซ๐ฒ
โWeโre advancing our proven growth strategy, which is resonating strongly with our customers, and our PPI Business System is enabling outstanding execution across the company.โ